Yahoo
Taipei Exchange - Delayed Quote TWD

SYN-TECH Chem. & Pharm. Co., Ltd. (1777.TWO)

76.90 +0.10 (+0.13%)
As of 1:08:12 PM GMT+8. Market Open.
Chart Range Bar
Loading chart for 1777.TWO
  • Previous Close 76.80
  • Open 76.00
  • Bid 77.00 x --
  • Ask 77.20 x --
  • Day's Range 76.00 - 77.20
  • 52 Week Range 70.00 - 80.00
  • Volume 52,646
  • Avg. Volume 42,214
  • Market Cap (intraday) 3.429B
  • Beta (5Y Monthly) -0.10
  • PE Ratio (TTM) 10.42
  • EPS (TTM) 7.41
  • Earnings Date --
  • Forward Dividend & Yield 4.00 (5.21%)
  • Ex-Dividend Date Jul 16, 2026
  • 1y Target Est --

SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relaxant, antitussive, antipruritic, scabicide, anti-inflammatory, antipyretic, analgesic, muscle relaxant, anxiolytic, antiemetic, anticonvulsant, anti-ulcerative, antihypertensive, a-blocker, vasodilator, bronchodilator, anxiolytic, tranquilizer, local anesthetic, decongestant, antispasmodic, neuroprotective, antimigraine, pharmaceutic aid/lubricant, antiglaucoma agent, hyponatremia, antidepressant, sedative, and analgesic, as well as treatment for hyperparathyroidism and urinary frequency, benign prostatic hypertrophy, and Herpes virus helicase-primase inhibitor. SYN-TECH Chem. & Pharm. Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.

www.syn-tech.com.tw

223

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

1777.TWO
10.48%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
55.76%

1-Year Return

1777.TWO
5.75%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
59.79%

3-Year Return

1777.TWO
6.71%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
175.14%

5-Year Return

1777.TWO
40.77%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
164.35%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY23
Revenue 271.89M
Earnings 25.47M
Profit Margin 9.37%

Q1

FY23

Q2

FY23

Q3

FY23

Q4

FY23

0
100M
200M
300M
10.0%
15.0%
20.0%
25.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.07%

  • Return on Assets (ttm)

    7.32%

  • Return on Equity (ttm)

    13.28%

  • Revenue (ttm)

    1.27B

  • Net Income Avi to Common (ttm)

    331.47M

  • Diluted EPS (ttm)

    7.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.11B

  • Total Debt/Equity (mrq)

    7.03%

  • Levered Free Cash Flow (ttm)

    184.19M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: